证券日报网讯药石科技（300725）9月15日在互动平台回答投资者提问时表示，截至2025年9月10日，公 司股东人数为47，205名。 ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-089 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于药石转债赎回实施暨即将停止转股的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后转股日：2025 年 9 月 17 日 2025 年 9 月 17 日收市前，持有"药石转债"的投资者仍可进行转股，2025 年 9 月 17 日收市后，未实施转股的"药石转债"将停止转股，剩余可转债将按 照 100.62 元/张的价格被强制赎回。若被强制赎回，投资者可能面临投资损失。 截至 2025 年 9 月 15 日收市后，距离 2025 年 9 月 18 日（"药石转债"赎回 日）仅剩 2 个交易日。 2、债券持有人若转股，需开通创业板交易权限。投资者不符合创业板股票 适当性管理要求的，不能将所持"药石转债"转换为股票，特提请投资者关注不 能转股的风险。 3、特提醒"药石转债"持有人注意在限期内转股。 特别提示： 1、" ...

Core Insights - The company maintains a "Buy" rating, reporting a revenue of 920 million yuan for H1 2025, representing a 23.48% increase, while net profit attributable to shareholders decreased by 26.54% to 72 million yuan [1] - The company is increasing investment in CMC resources to strengthen core customer relationships and market competitiveness, leading to revised EPS forecasts for 2025-2026 and a new forecast for 2027 [1] Revenue Performance - Revenue from drug research stage products and services was 154 million yuan, down 7.59%, with a gross margin of 57.29%, a decrease of 7.45 percentage points [2] - Revenue from drug development and commercialization stage products and services reached 765 million yuan, up 32.27%, with a gross margin of 25.69%, down 8.30 percentage points [2] Customer Structure and Order Growth - Revenue from Chinese customers was 261 million yuan, up 25.00%, while North American customers contributed 485 million yuan, up 8.65% [3] - The company has over 1,100 projects in early stages and 53 in clinical III and commercialization stages, with significant growth in new chemical entity orders and CDMO business [3] Catalysts - Order growth and capacity ramp-up are exceeding expectations, indicating strong future performance potential [4]

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-088 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于控股股东、实际控制人及其一致行动人权益变动触及1%整数倍的公告 | 权益变动过程 | | | | 2025年8月30日至2025年9月12日诺维科思通过大宗交易方式减持公司股 份100,000股。在此期间，公司可转债转股10,213,760股，公司总股本从 220,376,063股上升至230,589,823股，受此影响，控股股东、实际控制人 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 及其一致行动人持股变动占公司总股本比例为0.92%。本次权益变动后， | | | | | | | | | 公司控股股东、实际控制人及其一致行动人合计持有的公司股份 | | | | | | | | | | 43,689,328股，持股比例由19.87%下降至18.95%，股份变动触及1%整数倍。 | | | | 股票简称 | ...

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-087 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于药石转债赎回实施暨即将停止转股的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后转股日：2025 年 9 月 17 日 2025 年 9 月 17 日收市前，持有"药石转债"的投资者仍可进行转股，2025 年 9 月 17 日收市后，未实施转股的"药石转债"将停止转股，剩余可转债将按 照 100.62 元/张的价格被强制赎回。若被强制赎回，投资者可能面临投资损失。 截至 2025 年 9 月 12 日收市后，距离 2025 年 9 月 18 日（"药石转债"赎回 日）仅剩 3 个交易日。 2．债券持有人若转股，需开通创业板交易权限。投资者不符合创业板股票 适当性管理要求的，不能将所持"药石转债"转换为股票，特提请投资者关注不 能转股的风险。 3．特提醒"药石转债"持有人注意在限期内转股。 特别提示： 1、" ...

Core Viewpoint - The stock of Yaoshi Technology has experienced fluctuations, with a recent decline of 2.00% and a total market value of 9.392 billion yuan, reflecting mixed investor sentiment and market activity [1]. Financial Performance - For the first half of 2025, Yaoshi Technology reported a revenue of 920 million yuan, representing a year-on-year growth of 23.48%. However, the net profit attributable to shareholders decreased by 26.54% to 72.498 million yuan [2]. - Since its A-share listing, the company has distributed a total of 231 million yuan in dividends, with 137 million yuan distributed over the past three years [3]. Stock Market Activity - As of September 12, the stock price of Yaoshi Technology was 42.62 yuan per share, with a trading volume of 2.42 billion yuan and a turnover rate of 2.96% [1]. - The stock has seen a year-to-date increase of 27.91%, but has declined by 3.60% over the last five trading days and 10.93% over the last twenty days [1]. Shareholder Information - As of July 18, the number of shareholders for Yaoshi Technology increased to 36,500, a rise of 7.33%, while the average number of circulating shares per person decreased by 6.83% to 4,621 shares [2]. - The sixth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 2.1466 million shares, a decrease of 1.2259 million shares from the previous period [3].

Group 1 - The company Yaoshi Technology announced that there is only one trading day left until the trading of "Yaoshi Convertible Bonds" ceases on September 15, 2025 [2] - There are four trading days remaining until the conversion of "Yaoshi Convertible Bonds" into stocks ceases on September 18, 2025 [2] - Bondholders must open the ChiNext trading permissions to convert their bonds into stocks, and those who do not meet the suitability management requirements cannot convert their bonds [2]

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-086 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 1、最后交易日：2025 年 9 月 12 日 2025 年 9 月 12 日为"药石转债"最后一个交易日；当日"药石转债"简称 为"Z 石转债"；2025 年 9 月 12 日收市后"药石转债"将停止交易。 南京药石科技股份有限公司 关于药石转债赎回实施暨即将停止交易的重要提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 2、最后转股日：2025 年 9 月 17 日 2025 年 9 月 17 日收市前，持有"药石转债"的投资者仍可进行转股，2025 年 9 月 17 日收市后，未实施转股的"药石转债"将停止转股，剩余可转债将按 照 100.62 元/张的价格被强制赎回。若被强制赎回，投资者可能面临投资损失。 截至 2025 年 9 月 11 日收市后，距离 2025 年 9 月 15 日（"药石转债"停止 交易日）仅剩 1 个交易日；距离 20 ...

Core Viewpoint - A proposed executive order from the Trump administration is causing significant turmoil in the biopharmaceutical market, with major declines in stock prices for several companies [1][6]. Market Reaction - In the A-share market, companies such as Nossger, Huyou Pharmaceutical, and Tigermed saw declines exceeding 5%, with others like Yaoshi Technology and WuXi AppTec also following suit [1][2]. - The Hong Kong market's innovative drug concept index initially dropped over 7%, later narrowing to a 4.39% decline by midday [2]. Proposed Policy Impact - The New York Times reported that the proposed policy would require the FDA to conduct stricter reviews of clinical trial data from China, with companies submitting such data facing higher regulatory fees [3]. - If implemented, these restrictions could disrupt the U.S. pharmaceutical industry and affect the supply of all types of drugs, from generics to advanced therapies [6]. Industry Concerns - Analysts express that this "black swan" event could lead to a global supply chain restructuring, similar to the trade war during Trump's first term [7]. - The potential for drug shortages and rising prices in the U.S. market is a significant concern, particularly for generic drugs [7]. Investment Sentiment - Investor sentiment is divided, with some viewing the situation as a short-term emotional shock, while others worry that the end of the U.S. market could signal the end of the Chinese innovative drug bull market [9]. - Historical data suggests that after similar events, the pharmaceutical sector typically experiences a rebound within 2-4 weeks, with potential gains of 15%-20% [9].

Core Viewpoint - Nanjing Yaoshi Technology Co., Ltd. announced the implementation of the redemption of Yaoshi convertible bonds, which will cease trading soon, potentially leading to losses for investors [1] Group 1: Redemption Details - The last trading day for "Yaoshi Convertible Bonds" is September 12, 2025, and the last conversion day is September 17, 2025 [1] - Unconverted bonds will be forcibly redeemed at 100.62 CNY per bond after the market closes [1] Group 2: Trigger Conditions - From July 25, 2025, to August 14, 2025, the company's stock triggered conditional redemption clauses [1] - The company issued 11.5 million "Yaoshi Convertible Bonds" in 2022, with the latest conversion price set at 33.61 CNY per share [1] Group 3: Investor Considerations - Bondholders must open a ChiNext trading account to convert their bonds [1] - Investors are reminded to pay attention to risks and to convert within the specified period [1]